Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Phase 3 AMEERA-6 study expected to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting and will evaluate the safety and efficacy of Sanofi’s amcenestrant in ER+ patients who prematurely discontinue standard therapy.
Lead Product(s): Amcenestrant
Therapeutic Area: Oncology Product Name: SAR439859
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 04, 2021